Clinical research company Fortrea Holdings (NASDAQ: FTRE) will be announcing earnings results tomorrow morning. Here’s what to expect.
Fortrea beat analysts’ revenue expectations last quarter, reporting revenues of $701.3 million, up 3.9% year on year. It was a strong quarter for the company, with an impressive beat of analysts’ revenue estimates and full-year revenue guidance exceeding analysts’ expectations.
Is Fortrea a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Fortrea’s revenue to decline 4.3% year on year, a further deceleration from the 1.8% decrease it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Fortrea has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at Fortrea’s peers in the drug development inputs & services segment, some have already reported their Q4 results, giving us a hint as to what we can expect. UFP Technologies delivered year-on-year revenue growth of 3.4%, meeting analysts’ expectations, and Medpace reported revenues up 32%, topping estimates by 3.3%. Medpace traded down 15.9% following the results.
Read our full analysis of UFP Technologies’s results here and Medpace’s results here.
Investors in the drug development inputs & services segment have had fairly steady hands going into earnings, with share prices down 1.1% on average over the last month. Fortrea is down 36.8% during the same time and is heading into earnings with an average analyst price target of $16.44 (compared to the current share price of $10.98).
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
